MetaVia Inc (MetaVia), a subsidiary of Dong-A ST Co Ltd., develops and commercializes pharmaceuticals aimed at cardiometabolic diseases. The company emphasizes developing novel therapies for disorders including metabolic dysfunction-associated steatohepatitis (MASH) and obesity. MetaVia's principal programs include DA-1241, a G-Protein-Coupled Receptor 119 agonist, and DA-1726, an oxyntomodulin analogue. The company operates in the biotechnology and pharmaceutical sectors, focused on research and development, preclinical work, and clinical trials. MetaVia's portfolio comprises two primary programs: DA-1241 and DA-1726. DA-1241 is a new G-Protein-Coupled Receptor 119 agonist with potential as a monotherapy or combination treatment for MASH and Type 2 Diabetes Mellitus (T2DM). It stimulates release of important gut peptides involved in glucose and lipid metabolism and weight reduction. DA-1241 has demonstrated positive effects in preclinical studies and is now in Phase 2a clinical trials for MASH. DA-1726 is a new oxyntomodulin analogue acting as a GLP-1 receptor and glucagon receptor dual agonist for obesity therapy, intended for weekly subcutaneous injection. It has shown enhanced weight loss in preclinical models and is in Phase 1 trials. MetaVia also maintains four legacy therapeutic programs, including ANA001 for moderate COVID-19, NB-01 for painful diabetic neuropathy, NB-02 for cognitive impairment, and Gemcabene for dyslipidemia. The company’s activities mainly center on research and development, preclinical development, and clinical trials. The company reports one operating segment: pharmaceutical product development.

MetaVia initiatives focus on performing research and development activities, including preclinical developments and clinical trials. The company is engaged in developing novel drugs to address widespread and costly chronic diseases, with a particular focus on vanoglipel (DA-1241) for the treatment of MASH. The company aims to expand its pipeline by advancing drug compounds from ongoing discovery programs into clinical development. However, the process is expensive, time-consuming, and unpredictable, with significant risks and uncertainties, including the need for additional funding and regulatory approvals. The R&D unit of MetaVia is responsible for managing the company's research programs and product candidates for specific indications. This unit focuses on evaluating the commercial potential or target market for product candidates, managing clinical development, and ensuring compliance with regulatory requirements. The unit also oversees the controlled use of potentially hazardous substances in R&D activities. In FY2025, the company invested US$6.8 million.